FDA oks Sarepta muscular dystrophy drug after previous rejection

The U.S. FDA granted an accelerated approval to Sarepta Therapeutics ' therapy for Duchenne muscular dystrophy, reversing its original rejection.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news